BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 9293155)

  • 1. uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways?
    Blasi F
    Immunol Today; 1997 Sep; 18(9):415-7. PubMed ID: 9293155
    [No Abstract]   [Full Text] [Related]  

  • 2. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system.
    Blasi F
    Thromb Haemost; 1999 Aug; 82(2):298-304. PubMed ID: 10605717
    [No Abstract]   [Full Text] [Related]  

  • 3. Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role.
    Plebani M; Herszènyi L; Carraro P; De Paoli M; Roveroni G; Cardin R; Tulassay Z; Naccarato R; Farinati F
    Clin Exp Metastasis; 1997 Jul; 15(4):418-25. PubMed ID: 9219730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the serine proteinase system in chronic kidney rejection.
    Tang WH; Friess H; di Mola FF; Schilling M; Maurer C; Graber HU; Dervenis C; Zimmermann A; Büchler MW
    Transplantation; 1998 Jun; 65(12):1628-34. PubMed ID: 9665081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis.
    Choong PF; Nadesapillai AP
    Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S46-58. PubMed ID: 14600592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness.
    Buø L; Meling GI; Karlsrud TS; Johansen HT; Aasen AO
    Hum Pathol; 1995 Oct; 26(10):1133-8. PubMed ID: 7557947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system.
    Stahl A; Mueller BM
    Int J Cancer; 1997 Mar; 71(1):116-22. PubMed ID: 9096674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urokinase induces basophil chemotaxis through a urokinase receptor epitope that is an endogenous ligand for formyl peptide receptor-like 1 and -like 2.
    de Paulis A; Montuori N; Prevete N; Fiorentino I; Rossi FW; Visconte V; Rossi G; Marone G; Ragno P
    J Immunol; 2004 Nov; 173(9):5739-48. PubMed ID: 15494526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PAI-1 inhibits urokinase-induced chemotaxis by internalizing the urokinase receptor.
    Degryse B; Sier CF; Resnati M; Conese M; Blasi F
    FEBS Lett; 2001 Sep; 505(2):249-54. PubMed ID: 11566185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The urokinase-type plasminogen activator system and its role in tumor progression].
    Kugaevskaya EV; Gureeva TA; Timoshenko OS; Solovyeva NI
    Biomed Khim; 2018 Nov; 64(6):472-486. PubMed ID: 30632975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haemostatic factors occupy new territory: the role of the urokinase receptor system and kininogen in inflammation.
    Chavakis T; Kanse SM; May AE; Preissner KT
    Biochem Soc Trans; 2002 Apr; 30(2):168-73. PubMed ID: 12023845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.
    Fuessel S; Erdmann K; Taubert H; Lohse-Fischer A; Zastrow S; Meinhardt M; Bluemke K; Hofbauer L; Fornara P; Wullich B; Baretton G; Magdolen V; Wirth MP; Kotzsch M
    BMC Cancer; 2014 Dec; 14():974. PubMed ID: 25519168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of cell adhesion by PAI-1.
    Loskutoff DJ; Curriden SA; Hu G; Deng G
    APMIS; 1999 Jan; 107(1):54-61. PubMed ID: 10190280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urokinase receptor-dependent upregulation of smooth muscle cell adhesion to vitronectin by urokinase.
    Chang AW; Kuo A; Barnathan ES; Okada SS
    Arterioscler Thromb Vasc Biol; 1998 Dec; 18(12):1855-60. PubMed ID: 9848876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
    J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The urokinase receptor is required for human monocyte chemotaxis in vitro.
    Gyetko MR; Todd RF; Wilkinson CC; Sitrin RG
    J Clin Invest; 1994 Apr; 93(4):1380-7. PubMed ID: 8163642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
    Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
    Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deflazacort modulates the fibrinolytic pattern and reduces uPA-dependent chemioinvasion and proliferation in rheumatoid arthritis synoviocytes.
    Del Rosso A; Cinelli M; Guiducci S; Pignone A; Fibbi G; Margheri F; Gabrielli A; Giacomelli R; Coppini A; Del Rosso M; Matucci Cerinic M
    Rheumatology (Oxford); 2005 Oct; 44(10):1255-62. PubMed ID: 15998634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity.
    Fazioli F; Resnati M; Sidenius N; Higashimoto Y; Appella E; Blasi F
    EMBO J; 1997 Dec; 16(24):7279-86. PubMed ID: 9405357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation and role of urokinase plasminogen activator in vascular remodelling.
    Tkachuk V; Stepanova V; Little PJ; Bobik A
    Clin Exp Pharmacol Physiol; 1996 Sep; 23(9):759-65. PubMed ID: 8911711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.